Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Org Lett ; 22(15): 5844-5849, 2020 08 07.
Article in English | MEDLINE | ID: mdl-32678618

ABSTRACT

Saturated heterocyclic acetals are useful fragments in organic synthesis and other fields. Herein, C(sp3)-H dehydrogenative cross-couplings of ethers, tetrahydrothiophenes, and pyrrolidines were achieved under visible light irradiation by using iodobenzene and an in situ-formed gold complex. The broad functional group compatibility and substrate scope indicate that our strategy is a promising way to synthesize acetal analogues. The method was successfully applied in late-stage modifications of bioactive molecules. Gram scale syntheses and mechanistic studies are also presented.

2.
J Am Chem Soc ; 142(23): 10485-10493, 2020 06 10.
Article in English | MEDLINE | ID: mdl-32352770

ABSTRACT

Geminal diboronates have attracted significant attention because of their unique structures and reactivity. However, benzofuran-, indole-, and benzothiophene-based benzylic gem-diboronates, building blocks for biologically relevant compounds, are unknown. A promising protocol using visible light and aryl iodides for constructing valuable building blocks, including benzofuran-, indole-, and benzothiophene-based benzylic gem-diboronates, via radical carbo-cyclization/gem-diborylation of alkynes with a high functional group tolerance is presented. The utility of these gem-diboronates has been demonstrated by a 10 g scale conversion, by versatile transformations, by including the synthesis of approved drug scaffolds and two approved drugs, and even by polymer synthesis. The mechanistic investigation indicates that the merging of the dinuclear gold catalyst (photoexcitation by 315-400 nm UVA light) with Na2CO3 is directly responsible for photosensitization of aryl iodides (photoexcitation by 254 nm UV light) with blue LED light (410-490 nm, λmax = 465 nm) through an energy transfer (EnT) process, followed by homolytic cleavage of the C-I bond in the aryl iodide substrates.

3.
Org Lett ; 21(16): 6329-6332, 2019 08 16.
Article in English | MEDLINE | ID: mdl-31373208

ABSTRACT

Herein a synergistic combination of a nickel catalyst and benzaldehyde for the utilization of amides and thioethers in C(sp3)-H alkylation and arylation reactions employing simple aryl or alkyl halides is reported. This method provides a simple and cheap strategy for the direct functionalization of amides and thioethers. Readily available starting materials, mild reaction conditions, a good functional-group tolerance, and a broad substrate scope make this methodology attractive and practical for pharmaceutical and synthetic chemistry.

4.
Angew Chem Int Ed Engl ; 58(6): 1823-1827, 2019 Feb 04.
Article in English | MEDLINE | ID: mdl-30417501

ABSTRACT

Herein we report a highly selective photoredox C(sp3 )-H alkylation/arylation of ethers through the combination of a photo-organocatalyst (benzaldehyde) and a transition-metal catalyst (nickel). This method provides a simple and general strategy for the C(sp3 )-H alkylation/arylation of ethers. A selective late-stage modification of (-)-ambroxide has also been conducted to demonstrate the applicability of the method.

5.
J Med Chem ; 60(24): 10205-10219, 2017 12 28.
Article in English | MEDLINE | ID: mdl-29155585

ABSTRACT

SHP2, a cytoplasmic protein-tyrosine phosphatase encoded by the PTPN11 gene, is involved in multiple cell signaling processes including Ras/MAPK and Hippo/YAP pathways. SHP2 has been shown to contribute to the progression of a number of cancer types including leukemia, gastric, and breast cancers. It also regulates T-cell activation by interacting with inhibitory immune checkpoint receptors such as the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA). Thus, SHP2 inhibitors have drawn great attention by both inhibiting tumor cell proliferation and activating T cell immune responses toward cancer cells. In this study, we report the identification of an allosteric SHP2 inhibitor 1-(4-(6-bromonaphthalen-2-yl)thiazol-2-yl)-4-methylpiperidin-4-amine (23) that locks SHP2 in a closed conformation by binding to the interface of the N-terminal SH2, C-terminal SH2, and phosphatase domains. Compound 23 suppresses MAPK signaling pathway and YAP transcriptional activity and shows antitumor activity in vivo. The results indicate that allosteric inhibition of SHP2 could be a feasible approach for cancer therapy.


Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Enzyme Inhibitors/pharmacology , Naphthalenes/chemistry , Piperidines/chemistry , Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & inhibitors , Thiazoles/chemistry , Adaptor Proteins, Signal Transducing/antagonists & inhibitors , Administration, Oral , Allosteric Regulation/drug effects , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacokinetics , Binding Sites , Cell Proliferation/drug effects , Crystallography, X-Ray , Drug Screening Assays, Antitumor , Enzyme Inhibitors/chemistry , Female , Humans , Inhibitory Concentration 50 , MAP Kinase Signaling System/drug effects , Mice, Inbred BALB C , Mice, Nude , Mutation , Naphthalenes/administration & dosage , Naphthalenes/pharmacokinetics , Phosphoproteins/antagonists & inhibitors , Piperidines/administration & dosage , Piperidines/pharmacokinetics , Protein Tyrosine Phosphatase, Non-Receptor Type 11/chemistry , Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics , Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism , Structure-Activity Relationship , Thiazoles/administration & dosage , Thiazoles/pharmacokinetics , Transcription Factors , Xenograft Model Antitumor Assays , YAP-Signaling Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...